Tumor lysis syndrome: Pathophysiology, definition, and alternative treatment approaches

Gustavo Del Toro; Erin Morris; Mitchell S. Cairo

Tumor lysis syndrome: Pathophysiology, definition, and alternative treatment approaches

Gustavo Del Toro, Erin Morris, Mitchell S. Cairo

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

Tumor lysis syndrome (TLS), a life threatening metabolic syndrome seen in malignancies with high tumor burden, is reviewed in this article. The new Cairo and Bishop classification system is discussed as well as the clinical management of this syndrome. Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia.

Original language	English
Pages (from-to)	54-61
Number of pages	8
Journal	Clinical Advances in Hematology and Oncology
Volume	3
Issue number	1
State	Published - Jan 2005
Externally published	Yes

Keywords

Allopurinol
Cairo and Bishop classification system
Dialysis
Hyperkalemia
Hypocalcemia
Rasburicase
Tumor lysis syndrome
Urate oxidase
Urinary alkalinization

Cite this

@article{46bbccb2ed274654943266bbd69ae2c3,

title = "Tumor lysis syndrome: Pathophysiology, definition, and alternative treatment approaches",

abstract = "Tumor lysis syndrome (TLS), a life threatening metabolic syndrome seen in malignancies with high tumor burden, is reviewed in this article. The new Cairo and Bishop classification system is discussed as well as the clinical management of this syndrome. Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia.",

keywords = "Allopurinol, Cairo and Bishop classification system, Dialysis, Hyperkalemia, Hypocalcemia, Rasburicase, Tumor lysis syndrome, Urate oxidase, Urinary alkalinization",

author = "{Del Toro}, Gustavo and Erin Morris and Cairo, {Mitchell S.}",

year = "2005",

month = jan,

language = "English",

volume = "3",

pages = "54--61",

journal = "Clinical Advances in Hematology and Oncology",

issn = "1543-0790",

publisher = "Millennium Medical Publishing, Inc.",

number = "1",

}

TY - JOUR

T1 - Tumor lysis syndrome

T2 - Pathophysiology, definition, and alternative treatment approaches

AU - Del Toro, Gustavo

AU - Morris, Erin

AU - Cairo, Mitchell S.

PY - 2005/1

Y1 - 2005/1

N2 - Tumor lysis syndrome (TLS), a life threatening metabolic syndrome seen in malignancies with high tumor burden, is reviewed in this article. The new Cairo and Bishop classification system is discussed as well as the clinical management of this syndrome. Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia.

AB - Tumor lysis syndrome (TLS), a life threatening metabolic syndrome seen in malignancies with high tumor burden, is reviewed in this article. The new Cairo and Bishop classification system is discussed as well as the clinical management of this syndrome. Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia.

KW - Allopurinol

KW - Cairo and Bishop classification system

KW - Dialysis

KW - Hyperkalemia

KW - Hypocalcemia

KW - Rasburicase

KW - Tumor lysis syndrome

KW - Urate oxidase

KW - Urinary alkalinization

UR - http://www.scopus.com/inward/record.url?scp=14044267600&partnerID=8YFLogxK

M3 - Article

C2 - 16166968

AN - SCOPUS:14044267600

SN - 1543-0790

VL - 3

SP - 54

EP - 61

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

IS - 1

ER -

Tumor lysis syndrome: Pathophysiology, definition, and alternative treatment approaches

Abstract

Keywords

Fingerprint

Cite this